Clinical Profile Of Refractory Heart Failure And Its Outcome In Rural Institutional Setup

Parth Godhiwala
Sourya Acharya
Sunil Kumar
  1. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. ACC/AHA 2005 Guideline Update for
  2. the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of
  3. Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001
  4. Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American
  5. College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the
  6. Heart Rhythm Society. Circulation. 2005 Sep 20;112(12):e154-235.
  7. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. 2009 focused update incorporated
  8. into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the
  9. American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines:
  10. developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009
  11. Apr 14;119(14):e391-479.
  12. Seth S, Ramakrishnan S, Parekh N, Karthikeyan G, Singh S, Sharma G. Heart failure guidelines for India: Update
  13. J Pract Cardiovasc Sci. 2017 Sep 1;3(3):133.
  14. Schocken DD, Arrieta MI, Leaverton PE, Ross EA. Prevalence and mortality rate of congestive heart failure in the
  15. United States. J Am Coll Cardiol. 1992 Aug;20(2):301–6.
  16. Masoudi FA, Havranek EP, Krumholz HM. The Burden of Chronic Congestive Heart Failure in Older Persons:
  17. Magnitude and Implications for Policy and Research. Heart Fail Rev. 2002 Jan 1;7(1):9–16.
  18. Maestre A, Gil V, Gallego J, García M, García de Burgos F, Martín-Hidalgo A. Prediction clinical profile to
  19. distinguish between systolic and diastolic heart failure in hospitalized patients. Eur J Intern Med. 2009 May
  20. ;20(3):313–8.
  21. Dubourg O, Gueret P, Beauchet A, Nisse-Durgeat S, Ducardonnet A. Focale: Study of systolic and diastolic heart
  22. failure in a French elderly population. Int J Cardiol. 2008 Feb 29;124(2):188–92.
  23. Aurigemma GP, Gaasch WH. Clinical practice. Diastolic heart failure. N Engl J Med. 2004 Sep 9;351(11):1097–105.
  24. Reddy S, Bahl A, Talwar KK. Congestive heart failure in Indians: How do we improve diagnosis & management?
  25. Indian J Med Res. 2010 Nov;132(5):549–60.
  26. Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol. 2011 Jan;8(1):30–
  27. De Luca L, Fonarow GC, Adams KF, Mebazaa A, Tavazzi L, Swedberg K, et al. Acute heart failure syndromes:
  28. clinical scenarios and pathophysiologic targets for therapy. Heart Fail Rev. 2007 Jun;12(2):97–104.
  29. Reis FJFB dos, Fernandes AMS, Bitencourt AGV, Neves FBCS, Kuwano AY, França VHP, et al. Prevalence of anemia
  30. and renal insufficiency in non-hospitalized patients with heart failure. Arq Bras Cardiol. 2009 Sep;93(3):268–74.
  31. Feola M, Lombardo E, Testa M, Avogadri E, Piccolo S, Vado A. Prognostic factors of mid-term clinical outcome in
  32. congestive heart failure patients discharged after acute decompensation. Arch Med Sci AMS. 2012
  33. Jul 4;8(3):462–70.
  34. Nohria A, Lewis E, Stevenson LW. Medical management of advanced heart failure. JAMA. 2002
  35. Feb 6;287(5):628–40.
  36. Friedrich EB, Böhm M. Management of end stage heart failure. Heart. 2007 May;93(5):626–31.
  37. Jessup M, Brozena S. Heart failure. N Engl J Med. 2003 May 15;348(20):2007–18.
  38. Lip GYH, Gibbs CR, Beevers DG. Aetiology. BMJ. 2000 Jan 8;320(7227):104–7.
  39. McMurray JJ, Petrie MC, Murdoch DR, Davie AP. Clinical epidemiology of heart failure: public and private health
  40. burden. Eur Heart J. 1998 Dec;19 Suppl P:P9-16.
  41. Pereira-Barretto AC, Oliveira Junior MT de, Strunz CC, Del Carlo CH, Scipioni AR, Ramires JAF. Serum NT-proBNP
  42. levels are a prognostic predictor in patients with advanced heart failure. Arq Bras Cardiol. 2006 Aug;87(2):174–7.
  43. Witte KK, Clark AL. Why does chronic heart failure cause breathlessness and fatigue? Prog Cardiovasc Dis. 2007
  44. Apr;49(5):366–84.
  45. Willenheimer R, Erhardt LR. Value of 6-min-walk test for assessment of severity and prognosis of heart failure.
  46. Lancet Lond Engl. 2000 Feb 12;355(9203):515–6.
  47. Balashov K, Feldman DE, Savard S, Houde S, Frenette M, Ducharme A, et al. Percent predicted value for the 6-
  48. minute walk test: using norm-referenced equations to characterize severity in persons with CHF. J Card Fail. 2008
  49. Feb;14(1):75–81.
  50. ATS Statement. Am J Respir Crit Care Med. 2002 Jul 1;166(1):111–7.
  51. Bittner V, Weiner DH, Yusuf S, Rogers WJ, McIntyre KM, Bangdiwala SI, et al. Prediction of mortality and
  52. morbidity with a 6-minute walk test in patients with left ventricular dysfunction. SOLVD Investigators. JAMA. 1993
  53. Oct 13;270(14):1702–7.
  54. Wong M, Staszewsky L, Latini R, Barlera S, Glazer R, Aknay N, et al. Severity of left ventricular remodeling defines
  55. outcomes and response to therapy in heart failure: Valsartan heart failure trial (Val-HeFT) echocardiographic
  56. data. J Am Coll Cardiol. 2004 Jun 2;43(11):2022–7.
  57. Konstam Marvin A. Renal Function and Heart Failure Treatment. Circ Heart Fail. 2011 Nov 1;4(6):677–9.
  58. Cardiac Biomarkers and Heart Failure [Internet]. American College of Cardiology. [cited 2020 Aug 2]. Available
  59. from:
  60. biomarkers-and-heart-failure
  61. Ferrari R, Balla C, Fucili A. Heart failure: an historical perspective. Eur Heart J Suppl. 2016 Dec 1;18(suppl_G):G3–1
  62. Bianucci R, Loynes RD, Sutherland ML, Lallo R, Kay GL, Froesch P, et al. Forensic Analysis Reveals Acute
  63. Decompensation of Chronic Heart Failure in a 3500-Year-Old Egyptian Dignitary. J Forensic Sci.
  64. ;61(5):1378–81.
  65. Ferrari R. The story of the heartbeat, I: part I—heart rate: the rhythm of life. Eur Heart J. 2012 Jan;33(1):4–5.
  66. Laragh JH, Brenner BM. Hypertension: pathophysiology, diagnosis, and management.
  67. New York: Raven Press; 1995.
  68. Katz AM. The “modern” view of heart failure: how did we get here? Circ Heart Fail. 2008 May;1(1):63–71.
  69. Felker GM, O’Connor CM. Inotropic therapy for heart failure: an evidence-based approach. Am Heart J. 2001
  70. Sep;142(3):393–401.
  71. Harris P. Evolution and the cardiac patient. Cardiovasc Res. 1983 Aug;17(8):437–45.
  72. Anand IS, Kalra GS, Ferrari R, Harris P, Poole-Wilson PA. Hemodynamic, hormonal, and renal effects of atrial
  73. natriuretic peptide in untreated congestive cardiac failure. Am Heart J. 1989 Sep;118(3):500–5.
  74. Paulus WJ. Cytokines and heart failure. Heart Fail Monit. 2000;1(2):50–6.
  75. Ferrari R, Böhm M, Cleland JGF, Paulus WJS, Pieske B, Rapezzi C, et al. Heart failure with preserved ejection
  76. fraction: uncertainties and dilemmas. Eur J Heart Fail. 2015 Jul;17(7):665–71.
  77. Ferrari R. Ivabradine: Heart Rate and Left Ventricular Function. Cardiology. 2014;128(2):226–30.
  78. Sánchez PL, Fernández-Santos ME, Costanza S, Climent AM, Moscoso I, Gonzalez-Nicolas MA, et al. Acellular
  79. human heart matrix: A critical step toward whole heart grafts. Biomaterials. 2015 Aug;61:279–89.
  80. McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Dual angiotensin receptor and
  81. neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic
  82. systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine
  83. Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail. 2013
  84. Sep;15(9):1062–73.
  85. Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, et al. The angiotensin receptor neprilysin
  86. inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled
  87. trial. Lancet Lond Engl. 2012 Oct 20;380(9851):1387–95.
  88. McMurray JJV, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, et al. ESC guidelines for the
  89. diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and
  90. Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in
  91. collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012 Aug;14(8):803–69.
  92. Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, et al. Serelaxin, recombinant human
  93. relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet Lond
  94. Engl. 2013 Jan 5;381(9860):29–39.
  95. Tietjens J, Teerlink JR. Serelaxin and acute heart failure. Heart. 2016 Jan 15;102(2):95–9.
  96. 2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary | Circulation [Internet].
  97. [cited 2020 Aug 2]. Available from:
  98. Diagnosis and management of patients with heart failure [Internet]. Medical Laboratory Observer. 2017 [cited
  99. Aug 2]. Available from:
  100. and-management-of-patients-with-heart-failure
  102. Harrington RA, Narula J, Eapen ZJ, editors. Hurst’s The Heart [Internet]. 14th ed. New York, NY: McGraw-Hill
  103. Education; 2017 [cited 2020 Aug 2]. Available from:
  104. aid=1161716580
  105. Crespo‐Leiro MG, Metra M, Lund LH, Milicic D, Costanzo MR, Filippatos G, et al. Advanced heart failure: a position
  106. statement of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail.
  107. ;20(11):1505–35.
  108. Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the
  109. Heart Failure Association of the European Society of Cardiology – PubMed [Internet]. [cited 2020 Aug 2].
  110. Available from:
  111. Stevenson LW, Pagani FD, Young JB, Jessup M, Miller L, Kormos RL, et al. INTERMACS Profiles of Advanced Heart
  112. Failure: The Current Picture. J Heart Lung Transplant. 2009 Jun;28(6):535–41.
  113. Yancy Clyde W., Jessup Mariell, Bozkurt Biykem, Butler Javed, Casey Donald E., Drazner Mark H., et al. 2013
  114. ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary. Circulation. 2013 Oct
  115. ;128(16):1810–52.
  116. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis
  117. and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and
  118. chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the
  119. Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016 14;37(27):2129–200.
  120. Cowie MR, Filippatos GS, Alonso Garcia M de LA, Anker SD, Baczynska A, Bloomfield DM, et al. New medicinal
  121. products for chronic heart failure: advances in clinical trial design and efficacy assessment. Eur J Heart Fail.
  122. ;19(6):718–27.
  123. Borne RT, Varosy PD, Masoudi FA. Implantable Cardioverter-Defibrillator Shocks: Epidemiology, Outcomes, and
  124. Therapeutic Approaches. JAMA Intern Med. 2013 May 27;173(10):859–65.
  125. Triposkiadis F, Giamouzis G, Parissis J, Starling RC, Boudoulas H, Skoularigis J, et al. Reframing the association
  126. and significance of co-morbidities in heart failure. Eur J Heart Fail. 2016;18(7):744–58.
  127. Dc C, Rd Y, Ws C, Sb G, Ay K, K K, et al. The Registry of the International Society for Heart and Lung
  128. Transplantation: Thirty-fourth Adult Lung And Heart-Lung Transplantation Report-2017; Focus Theme: Allograft
  129. ischemic time. J Heart Lung Transplant Off Publ Int Soc Heart Transplant. 2017 Jul 19;36(10):1047–59.
  130. Ezekowitz JA, Kaul P, Bakal JA, Quan H, McAlister FA. Trends in heart failure care: has the incident diagnosis of
  131. heart failure shifted from the hospital to the emergency department and outpatient clinics? Eur J Heart Fail.
  132. Feb;13(2):142–7.
  133. Senni M, Tribouilloy CM, Rodeheffer RJ, Jacobsen SJ, Evans JM, Bailey KR, et al. Congestive heart failure in the
  134. community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation. 1998 Nov
  135. ;98(21):2282–9.
  136. Cowie MR, Wood DA, Coats AJ, Thompson SG, Poole-Wilson PA, Suresh V, et al. Incidence and aetiology of heart
  137. failure; a population-based study. Eur Heart J. 1999 Mar;20(6):421–8.
  138. de Giuli F, Khaw K-T, Cowie MR, Sutton GC, Ferrari R, Poole-Wilson PA. Incidence and outcome of persons with a
  139. clinical diagnosis of heart failure in a general practice population of 696,884 in the United Kingdom. Eur J Heart
  140. Fail. 2005 Mar 16;7(3):295–302.
  141. Murphy NF, Simpson CR, MacIntyre K, McAlister FA, Chalmers J, McMurray JJV. Prevalence, incidence, primary
  142. care burden and medical treatment of angina in Scotland: age, sex and socioeconomic disparities: a population‐
  143. based study. Heart. 2006 Aug;92(8):1047–54.
  144. Parameshwar J, Shackell MM, Richardson A, Poole-Wilson PA, Sutton GC. Prevalence of heart failure in three
  145. general practices in north west London. Br J Gen Pract J R Coll Gen Pract. 1992 Jul;42(360):287–9.
  146. Dahlstrom U, Hakansson J, Swedberg K, Waldenstrom A. Adequacy of diagnosis and treatment of chronic heart
  147. failure in primary health care in Sweden. Eur J Heart Fail. 2009 Jan;11(1):92–8.
  148. Rutten FH, Grobbee DE, Hoes AW. Diagnosis and management of heart failure: a questionnaire among general
  149. practitioners and cardiologists. Eur J Heart Fail. 2003 Jun;5(3):345–8.
  150. McDonagh TA, Morrison CE, Lawrence A, Ford I, Tunstall-Pedoe H, McMurray JJ, et al. Symptomatic and
  151. asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet Lond Engl. 1997 Sep
  152. ;350(9081):829–33.
  153. Davies M, Hobbs F, Davis R, Kenkre J, Roalfe AK, Hare R, et al. Prevalence of left-ventricular systolic dysfunction
  154. and heart failure in the Echocardiographic Heart of England Screening study: a population based study. Lancet
  155. Lond Engl. 2001 Aug 11;358(9280):439–44.
  156. Ceia F, Fonseca C, Mota T, Morais H, Matias F, de Sousa A, et al. Prevalence of chronic heart failure in
  157. Southwestern Europe: the EPICA study. Eur J Heart Fail. 2002 Aug;4(4):531–9.
  158. Guha K, McDonagh T. Heart Failure Epidemiology: European Perspective. Curr Cardiol Rev. 2013 May;9(2):123–7.
  159. Vaes B, Rezzoug N, Pasquet A, Wallemacq P, Van Pottelbergh G, Matheï C, et al. The prevalence of cardiac
  160. dysfunction and the correlation with poor functioning among the very elderly. Int J Cardiol. 2012 Feb
  161. ;155(1):134–43.
  162. Braunschweig F, Cowie MR, Auricchio A. What are the costs of heart failure? Eur Eur Pacing Arrhythm Card
  163. Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol. 2011 May;13 Suppl
  164. :ii13-17.
  165. Stewart S, MacIntyre K, MacLeod MM, Bailey AE, Capewell S, McMurray JJ. Trends in hospitalization for heart
  166. failure in Scotland, 1990-1996. An epidemic that has reached its peak? Eur Heart J. 2001 Feb;22(3):209–17.
  167. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart Br Card Soc. 2007 Sep;93(9):1137–46.
  168. Huffman MD, Prabhakaran D. Heart failure: Epidemiology and prevention in India. Natl Med J INDIA.
  169. ;23(5):6.
  170. Libby PP, Bonow RO, Mann DL, Zipes DP. Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine. 8th
  171. edition. 2007 [cited 2020 Aug 2]; Available from:
  173. cardiovascular-medicine-8t-2
  174. Thakur JS, Negi PC, Ahluwalia SK, Vaidya NK. Epidemiological survey of rheumatic heart disease among school
  175. children in the Shimla Hills of northern India: prevalence and risk factors. J Epidemiol Community Health. 1996
  176. Feb;50(1):62–7.
  177. J M, Bm M. Penicillin for secondary prevention of rheumatic fever [Internet]. Vol. 2002, The Cochrane database of
  178. systematic reviews. Cochrane Database Syst Rev; 2002 [cited 2020 Aug 2]. Available from:
  180. Ali MK, Narayan KMV, Mohan V. Innovative research for equitable diabetes care in India. Diabetes Res Clin Pract.
  181. Dec;86(3):155–67.
  182. Xavier D, Pais P, Devereaux PJ, Xie C, Prabhakaran D, Reddy KS, et al. Treatment and outcomes of acute coronary
  183. syndromes in India (CREATE): a prospective analysis of registry data. Lancet Lond Engl. 2008 Apr
  184. ;371(9622):1435–42.
  185. WHO | Commission on Social Determinants of Health – final report [Internet]. WHO. World Health Organization;
  186. [cited 2020 Aug 2]. Available from:
  187. WRITING GROUP MEMBERS, Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, et al. Heart disease and
  188. stroke statistics–2010 update: a report from the American Heart Association. Circulation.
  189. Feb 23;121(7):e46–215.
  190. Nieminen MS, Brutsaert D, Dickstein K, Drexler H, Follath F, Harjola V-P, et al. EuroHeart Failure Survey II (EHFS
  191. II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J. 2006
  192. Nov;27(22):2725–36.
  193. Blackledge HM, Newton J, Squire IB. Prognosis for South Asian and white patients newly admitted to hospital
  194. with heart failure in the United Kingdom: historical cohort study. BMJ. 2003 Sep 6;327(7414):526–31.
  195. Brink AJ, Aalbers J. Strategies for heart disease in sub-Saharan Africa. Heart Br Card Soc. 2009
  196. Oct;95(19):1559–60.
  197. Heart failure in India: The INDUS (INDia Ukieri Study) study Chaturvedi V, Parakh N, Seth S, Bhargava B,
  198. Ramakrishnan S, Roy A, Saxena A, Gupta N, Misra P, Rai SK, Anand K, Pandav CS, Sharma R, Prasad S – J Pract
  199. Cardiovasc Sci [Internet]. [cited 2020 Aug 2]. Available from:
  200. ;year=2016;volume=2;issue=1;spage=28;epage=35;aulast=Chaturvedi
  201. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJL. Global and regional burden of disease and risk factors,
  202. : systematic analysis of population health data. Lancet Lond Engl. 2006 May 27;367(9524):1747–57.
  203. Strasser T, Dondog N, El Kholy A, Gharagozloo R, Kalbian VV, Ogunbi O, et al. The community control of
  204. rheumatic fever and rheumatic heart disease: report of a WHO international cooperative project. Bull World
  205. Health Organ. 1981;59(2):285–94.
  206. Rizvi SF, Khan MA, Kundi A, Marsh DR, Samad A, Pasha O. Status of rheumatic heart disease in rural Pakistan.
  207. Heart Br Card Soc. 2004 Apr;90(4):394–9.
  208. Arora R, Subramanyam G, Khalilullah M, Gupta MP. Clinical profile of rheumatic fever and rheumatic heart d
  209. isease: a study of 2,500 cases. Indian Heart J. 1981 Dec;33(6):264–9.
  210. Meenakshisundaram R, Thirumalaikolundusubramanian P. Valvular heart disease in Indian subcontinent: Social
  211. issues. Indian J Community Med. 2009 Jan 1;34(1):57.
  212. Kumar R, Raizada A, Aggarwal AK, Ganguly NK. A community-based rheumatic fever/rheumatic heart disease
  213. cohort: twelve-year experience. Indian Heart J. 2002 Feb;54(1):54–8.
  214. Grover A, Dhawan A, Iyengar SD, Anand IS, Wahi PL, Ganguly NK. Epidemiology of rheumatic fever and
  215. rheumatic heart disease in a rural community in northern India. Bull World Health Organ. 1993;71(1):59–66.
  216. A G, R V, St T. Burden of rheumatic and congenital heart disease in India: lowest estimate based on the 2001
  217. census. Indian Heart J. 2002 Jan 1;54(1):104–7.
  218. Spencer FA, Meyer TE, Gore JM, Goldberg RJ. Heterogeneity in the management and outcomes of patients with
  219. acute myocardial infarction complicated by heart failure: the National Registry of Myocardial Infarction.
  220. Circulation. 2002 Jun 4;105(22):2605–10.
  221. Velagaleti RS, Pencina MJ, Murabito JM, Wang TJ, Parikh NI, D’Agostino RB, et al. Long-term trends in the
  222. incidence of heart failure after myocardial infarction. Circulation. 2008 Nov 11;118(20):2057–62.
  223. Mehta SR, Yusuf S, Díaz R, Zhu J, Pais P, Xavier D, et al. Effect of glucose-insulin-potassium infusion on mortality
  224. in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled
  225. trial. JAMA. 2005 Jan 26;293(4):437–46.
  226. Holay MP, Janbandhu A, Javahirani A, Pandharipande MS, Suryawanshi SD. Clinical profile of acute myocardial
  227. infarction in elderly (prospective study). J Assoc Physicians India. 2007 Mar;55:188–92.
  228. Prabhakaran D, Yusuf S, Mehta S, Pogue J, Avezum A, Budaj A, et al. Two-year outcomes in patients admitted
  229. with non-ST elevation acute coronary syndrome: results of the OASIS registry 1 and 2. Indian Heart J. 2005
  230. Jun;57(3):217–25.
  231. Gupta R. Trends in hypertension epidemiology in India. J Hum Hypertens. 2004 Feb;18(2):73–8.
  232. Gupta R, Joshi P, Mohan V, Reddy KS, Yusuf S. Epidemiology and causation of coronary heart disease and stroke
  233. in India. Heart Br Card Soc. 2008 Jan;94(1):16–26.
  234. Fox KM, EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease
  235. Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary
  236. artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet
  237. Lond Engl. 2003 Sep 6;362(9386):782–8.
  238. Lawes CMM, Vander Hoorn S, Rodgers A, International Society of Hypertension. Global burden of blood-
  239. pressure-related disease, 2001. Lancet Lond Engl. 2008 May 3;371(9623):1513–8.
  240. Drazner MH, Rame JE, Marino EK, Gottdiener JS, Kitzman DW, Gardin JM, et al. Increased left ventricular
  241. mass is a risk factor for the development of a depressed left ventricular ejection fraction within five years:
  242. the Cardiovascular Health Study. J Am Coll Cardiol. 2004 Jun 16;43(12):2207–15.
  243. Okin PM, Devereux RB, Nieminen MS, Jern S, Oikarinen L, Viitasalo M, et al. Electrocardiographic strain
  244. pattern and prediction of new-onset congestive heart failure in hypertensive patients: the Losartan
  245. Intervention for Endpoint Reduction in Hypertension (LIFE) study. Circulation. 2006 Jan 3;113(1):67–73.
  246. Association of Blood Pressure and Cardiovascular Mortality in India: Mumbai Cohort Study | American
  247. Journal of Hypertension | Oxford Academic [Internet]. [cited 2020 Aug 2]. Available from:
  249. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart
  250. failure. JAMA. 1996 May 22;275(20):1557–62.
  251. Tocci G, Sciarretta S, Volpe M. Development of heart failure in recent hypertension trials. J Hypertens. 2008 Jul;26(7):1477–86.
  252. Kenchaiah S, Evans JC, Levy D, Wilson PWF, Benjamin EJ, Larson MG, et al. Obesity and the risk of heart failure. N Engl J Med. 2002 Aug 1;347(5):305–13.
  253. Reddy KS, Prabhakaran D, Shah P, Shah B. Differences in body mass index and waist: hip ratios in North Indian rural and urban populations. Obes Rev Off J Int Assoc Study Obes. 2002 Aug;3(3):197–202.
  254. The need for obtaining accurate nationwide estimates of diabetes prevalence in India – Rationale for a national study on diabetes Anjana R M, Ali M K, Pradeepa R, Deepa M, Datta M, Unnikrishnan R, Rema M, Mohan V – Indian J Med Res [Internet]. [cited 2020 Aug 2]. Available from:;year=2011;volume=133;issue=4;spage=369;epage=380;aulast=Anjana
  255. Rodgers A, Ezzati M, Vander Hoorn S, Lopez AD, Lin R-B, Murray CJL, et al. Distribution of major health risks: findings from the Global Burden of Disease study. PLoS Med. 2004 Oct;1(1):e27.
  256. Miller LW. Left ventricular assist devices are underutilized. Circulation. 2011 Apr 12;123(14):1552–8; discussion 1558.
  257. Gheorghiade M, Cody RJ, Francis GS, McKenna WJ, Young JB, Bonow RO. Current medical therapy for advanced heart failure. Heart Lung J Crit Care. 2000 Feb;29(1):16–32.
  258. Zannad F, Briancon S, Juilliere Y, Mertes PM, Villemot JP, Alla F, et al. Incidence, clinical and etiologic features, and outcomes of advanced chronic heart failure: the EPICAL Study. Epidémiologie de l’Insuffisance Cardiaque Avancée en Lorraine. J Am Coll Cardiol. 1999 Mar;33(3):734–42.
  259. AbouEzzeddine OF, Redfield MM. Who Has Advanced Heart Failure? Definition and Epidemiology. Congest Heart Fail Greenwich Conn [Internet]. 2011 [cited 2020 Aug 3];17(4). Available from:
  260. Types of heart failure [Internet]. [Internet]. Institute for Quality and Efficiency in Health Care (IQWiG); 2018 [cited 2020 Aug 3]. Available from:
  261. Tanai E, Frantz S. Pathophysiology of Heart Failure. Compr Physiol. 2015 Dec 15;6(1):187–214.
  262. de Mello BHG, Oliveira GBF, Ramos RF, Lopes BBC, Barros CBS, Carvalho E de O, et al. Validation of the Killip-Kimball Classification and Late Mortality after Acute Myocardial Infarction. Arq Bras Cardiol. 2014 Aug;103(2):107–17.
  263. Forrester JS, Diamond GA, Swan HJ. Correlative classification of clinical and hemodynamic function after acute myocardial infarction. Am J Cardiol. 1977 Feb;39(2):137–45.
  264. Schocken DD, Benjamin EJ, Fonarow GC, Krumholz HM, Levy D, Mensah GA, et al. Prevention of heart failure: a scientific statement from the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation. 2008 May 13;117(19):2544–65.
  265. Census of India : Provisional Population Totals India : Paper1 : Census 2011 [Internet]. [cited 2020 Aug 2]. Available from:
  266. Loehr LR, Rosamond WD, Chang PP, Folsom AR, Chambless LE. Heart failure incidence and survival (from the Atherosclerosis Risk in Communities study). Am J Cardiol. 2008 Apr 1;101(7):1016–22.
  267. Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D’Agostino RB, Kannel WB, et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation. 2002 Dec 10;106(24):3068–72.
  268. Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, et al. Factors identified as precipitating hospital admissions for heart failure and clinical outcomes: findings from OPTIMIZE-HF. Arch Intern Med. 2008 Apr 28;168(8):847–54.
  269. Hellermann JP, Goraya TY, Jacobsen SJ, Weston SA, Reeder GS, Gersh BJ, et al. Incidence of heart failure after myocardial infarction: is it changing over time? Am J Epidemiol. 2003 Jun 15;157(12):1101–7.
  270. Goldberg RJ, Spencer FA, Yarzebski J, Lessard D, Gore JM, Alpert JS, et al. A 25-year perspective into the changing landscape of patients hospitalized with acute myocardial infarction (the Worcester Heart Attack Study). Am J Cardiol. 2004 Dec 1;94(11):1373–8.
  271. Mosterd A, Hoes AW, de Bruyne MC, Deckers JW, Linker DT, Hofman A, et al. Prevalence of heart failure and left ventricular dysfunction in the general population; The Rotterdam Study. Eur Heart J. 1999 Mar;20(6):447–55.
  272. Bibbins-Domingo K, Lin F, Vittinghoff E, Barrett-Connor E, Hulley SB, Grady D, et al. Predictors of heart failure among women with coronary disease. Circulation. 2004 Sep 14;110(11):1424–30.
  273. From AM, Leibson CL, Bursi F, Redfield MM, Weston SA, Jacobsen SJ, et al. Diabetes in heart failure: prevalence and impact on outcome in the population. Am J Med. 2006 Jul;119(7):591–9.
  274. Gottdiener JS, Arnold AM, Aurigemma GP, Polak JF, Tracy RP, Kitzman DW, et al. Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. J Am Coll Cardiol. 2000 May;35(6):1628–37.
  275. Suskin N, Sheth T, Negassa A, Yusuf S. Relationship of current and past smoking to mortality and morbidity in patients with left ventricular dysfunction. J Am Coll Cardiol. 2001 May;37(6):1677–82.
  276. Lee DS, Gona P, Vasan RS, Larson MG, Benjamin EJ, Wang TJ, et al. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the framingham heart study of the national heart, lung, and blood institute. Circulation. 2009 Jun 23;119(24):3070–7.
  277. Goldberg RJ, Spencer FA, Farmer C, Meyer TE, Pezzella S. Incidence and hospital death rates associated with heart failure: a community-wide perspective. Am J Med. 2005 Jul;118(7):728–34.
  278. Djoussé L, Kurth T, Gaziano JM. Cystatin C and risk of heart failure in the Physicians’ Health Study (PHS). Am Heart J. 2008 Jan;155(1):82–6.
  279. Bibbins-Domingo K, Lin F, Vittinghoff E, Barrett-Connor E, Grady D, Shlipak MG. Renal insufficiency as an independent predictor of mortality among women with heart failure. J Am Coll Cardiol. 2004 Oct 19;44(8):1593–600.
  280. Masoudi FA, Krumholz HM. Polypharmacy and comorbidity in heart failure. BMJ. 2003 Sep 6;327(7414):513–4.
  281. Havranek EP, Masoudi FA, Westfall KA, Wolfe P, Ordin DL, Krumholz HM. Spectrum of heart failure in older patients: results from the National Heart Failure project. Am Heart J. 2002 Mar;143(3):412–7.
  282. Braunstein JB, Anderson GF, Gerstenblith G, Weller W, Niefeld M, Herbert R, et al. Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. J Am Coll Cardiol. 2003 Oct 1;42(7):1226–33.
  283. Yusuf S, Rangarajan S, Teo K, Islam S, Li W, Liu L, et al. Cardiovascular risk and events in 17 low-, middle-, and high-income countries. N Engl J Med. 2014 28;371(9):818–27.
  284. Hawkins NM, Petrie MC, Jhund PS, Chalmers GW, Dunn FG, McMurray JJV. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail. 2009 Feb;11(2):130–9.
  285. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet Lond Engl. 2012 Dec 15;380(9859):2163–96.
  286. Djoussé L, Driver JA, Gaziano JM. Relation between modifiable lifestyle factors and lifetime risk of heart failure. JAMA. 2009 Jul 22;302(4):394–400.
  287. Ziaeian B, Fonarow GC. Epidemiology and aetiology of heart failure. Nat Rev Cardiol. 2016 Jun;13(6):368–78.
  288. Nabel EG, Braunwald E. A tale of coronary artery disease and myocardial infarction. N Engl J Med. 2012 Jan 5;366(1):54–63.
  289. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet Lond Engl. 2015 Jan 10;385(9963):117–71.
  290. Moran AE, Forouzanfar MH, Roth GA, Mensah GA, Ezzati M, Flaxman A, et al. The global burden of ischemic heart disease in 1990 and 2010: the Global Burden of Disease 2010 study. Circulation. 2014 Apr 8;129(14):1493–501.
  291. Zarrinkoub R, Wettermark B, Wändell P, Mejhert M, Szulkin R, Ljunggren G, et al. The epidemiology of heart failure, based on data for 2.1 million inhabitants in Sweden. Eur J Heart Fail. 2013 Sep;15(9):995–1002.
  292. Gerber Y, Weston SA, Redfield MM, Chamberlain AM, Manemann SM, Jiang R, et al. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA Intern Med. 2015 Jun;175(6):996–1004.
  293. Brouwers FP, van Gilst WH, van Veldhuisen DJ. The changing face of heart failure: are we really making progress? Eur J Heart Fail. 2013 Sep;15(9):960–2.
  294. Drazner MH. The progression of hypertensive heart disease. Circulation. 2011 Jan 25;123(3):327–34.
  295. Egan BM, Li J, Hutchison FN, Ferdinand KC. Hypertension in the United States, 1999 to 2012: progress toward Healthy People 2020 goals. Circulation. 2014 Nov 4;130(19):1692–9.
  296. Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KKL, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 2002 Oct 31;347(18):1397–402.
  297. Ojji D, Stewart S, Ajayi S, Manmak M, Sliwa K. A predominance of hypertensive heart failure in the Abuja Heart Study cohort of urban Nigerians: a prospective clinical registry of 1515 de novo cases. Eur J Heart Fail. 2013 Aug;15(8):835–42.
  298. Chow CK, Teo KK, Rangarajan S, Islam S, Gupta R, Avezum A, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA. 2013 Sep 4;310(9):959–68.
  299. Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. Lancet Lond Engl. 2006 Sep 16;368(9540):1005–11.
  300. Essop MR, Nkomo VT. Rheumatic and nonrheumatic valvular heart disease: epidemiology, management, and prevention in Africa. Circulation. 2005 Dec 6;112(23):3584–91.
  301. Marijon E, Ou P, Celermajer DS, Ferreira B, Mocumbi AO, Jani D, et al. Prevalence of rheumatic heart disease detected by echocardiographic screening. N Engl J Med. 2007 Aug 2;357(5):470–6.
  302. Baldasseroni S, Opasich C, Gorini M, Lucci D, Marchionni N, Marini M, et al. Left bundle-branch block is associated with increased 1-year sudden and total mortality rate in 5517 outpatients with congestive heart failure: a report from the Italian network on congestive heart failure. Am Heart J. 2002 Mar;143(3):398–405.
  303. Sliwa K, Damasceno A, Mayosi BM. Epidemiology and etiology of cardiomyopathy in Africa. Circulation. 2005 Dec 6;112(23):3577–83.
  304. Moran A, Forouzanfar M, Sampson U, Chugh S, Feigin V, Mensah G. The epidemiology of cardiovascular diseases in sub-Saharan Africa: the Global Burden of Diseases, Injuries and Risk Factors 2010 Study. Prog Cardiovasc Dis. 2013 Dec;56(3):234–9.
  305. Mayosi BM. Contemporary trends in the epidemiology and management of cardiomyopathy and pericarditis in sub-Saharan Africa. Heart Br Card Soc. 2007 Oct;93(10):1176–83.
  306. Cooper LT, Keren A, Sliwa K, Matsumori A, Mensah GA. The global burden of myocarditis: part 1: a systematic literature review for the Global Burden of Diseases, Injuries, and Risk Factors 2010 study. Glob Heart. 2014 Mar;9(1):121–9.
  307. Bern C. Chagas’ Disease. N Engl J Med. 2015 Jul 30;373(5):456–66.
  308. Bern C, Montgomery SP. An estimate of the burden of Chagas disease in the United States. Clin Infect Dis Off Publ Infect Dis Soc Am. 2009 Sep 1;49(5):e52-54.
  309. Rassi A, Rassi A, Marin-Neto JA. Chagas disease. Lancet Lond Engl. 2010 Apr 17;375(9723):1388–402.
  310. Morillo CA, Marin-Neto JA, Avezum A, Sosa-Estani S, Rassi A, Rosas F, et al. Randomized Trial of Benznidazole for Chronic Chagas’ Cardiomyopathy. N Engl J Med. 2015;373(14):1295–306.
  311. van der Bom T, Zomer AC, Zwinderman AH, Meijboom FJ, Bouma BJ, Mulder BJM. The changing epidemiology of congenital heart disease. Nat Rev Cardiol. 2011 Jan;8(1):50–60.
  312. Diller G-P, Dimopoulos K, Okonko D, Li W, Babu-Narayan SV, Broberg CS, et al. Exercise intolerance in adult congenital heart disease: comparative severity, correlates, and prognostic implication. Circulation. 2005 Aug 9;112(6):828–35.
  313. Fredriksen PM, Veldtman G, Hechter S, Therrien J, Chen A, Warsi MA, et al. Aerobic capacity in adults with various congenital heart diseases. Am J Cardiol. 2001 Feb 1;87(3):310–4.
  314. Zühlke L, Mirabel M, Marijon E. Congenital heart disease and rheumatic heart disease in Africa: recent advances and current priorities. Heart Br Card Soc. 2013 Nov;99(21):1554–61.
  315. Fuster V, Harrington RA, Narula J, Eapen ZJ. Hurst’s the Heart, 14th Edition: Two Volume Set. McGraw Hill Professional; 2017. 2613 p.
  316. Yin Z, Ren J, Guo W. Sarcomeric Protein Isoform Transitions in Cardiac Muscle: A Journey to Heart Failure. Biochim Biophys Acta. 2015 Jan;1852(1):47–52.
  317. Lowes BD, Baker ML, Blaxall BC. Editorial Gene expression profile of the recovering human heart. 2007.
  318. Kaya Z, Leib C, Katus HA. Autoantibodies in heart failure and cardiac dysfunction. Circ Res. 2012 Jan 6;110(1):145–58.
  319. Prospective familial assessment in dilated cardiomyopathy: cardiac autoantibodies predict disease development in asymptomatic relatives – PubMed [Internet]. [cited 2020 Aug 4]. Available from:
  320. Gorski PA, Ceholski DK, Hajjar RJ. Altered myocardial calcium cycling and energetics in heart failure – a rational approach for disease treatment. Cell Metab. 2015 Feb 3;21(2):183–94.
  321. Inherited disorders of voltage-gated sodium channels – PubMed [Internet]. [cited 2020 Aug 4]. Available from:
  322. Calcium cycling proteins and heart failure: mechanisms and therapeutics – PubMed [Internet]. [cited 2020 Aug 4]. Available from:
  323. Cardiac Metabolism as a Target for the Treatment of Heart Failure | Circulation [Internet]. [cited 2020 Aug 4]. Available from:
  324. Ardehali H, Sabbah HN, Burke MA, Sarma S, Liu PP, Cleland JGF, et al. Targeting myocardial substrate metabolism in heart failure: potential for new therapies. Eur J Heart Fail. 2012 Feb;14(2):120–9.
  325. Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev. 2005 Jul;85(3):1093–129.
  326. Rajabi M, Kassiotis C, Razeghi P, Taegtmeyer H. Return to the fetal gene program protects the stressed heart: a strong hypothesis. Heart Fail Rev. 2007 Dec;12(3–4):331–43.
  327. Eberli FR, Weinberg EO, Grice WN, Horowitz GL, Apstein CS. Protective effect of increased glycolytic substrate against systolic and diastolic dysfunction and increased coronary resistance from prolonged global underperfusion and reperfusion in isolated rabbit hearts perfused with erythrocyte suspensions. Circ Res. 1991 Feb;68(2):466–81.
  328. Neubauer S, Horn M, Cramer M, Harre K, Newell JB, Peters W, et al. Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation. 1997 Oct 7;96(7):2190–6.
  329. Bayeva M, Gheorghiade M, Ardehali H. Mitochondria as a therapeutic target in heart failure. J Am Coll Cardiol. 2013 Feb 12;61(6):599–610.
  330. Mayr JA, Haack TB, Graf E, Zimmermann FA, Wieland T, Haberberger B, et al. Lack of the mitochondrial protein acylglycerol kinase causes Sengers syndrome. Am J Hum Genet. 2012 Feb 10;90(2):314–20.
  331. Chen HH, Schrier RW. Pathophysiology of volume overload in acute heart failure syndromes. Am J Med. 2006 Dec;119(12 Suppl 1):S11-16.
  332. Dube P, Weber KT, Weber KT. Congestive Heart Failure: Pathophysiologic Consequences of Neurohormonal Activation and the Potential for Recovery: Part II. Am J Med Sci. 2011 Dec 1;342(6):503–6.
  333. Volpe M, Carnovali M, Mastromarino V. The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment. Clin Sci Lond Engl 1979. 2016 Jan;130(2):57–77.
  334. Braunwald E. The path to an angiotensin receptor antagonist-neprilysin inhibitor in the treatment of heart failure. J Am Coll Cardiol. 2015 Mar 17;65(10):1029–41.
  335. Florea VG, Cohn JN. The autonomic nervous system and heart failure. Circ Res. 2014 May 23;114(11):1815–26.
  336. Cohn JN, Pfeffer MA, Rouleau J, Sharpe N, Swedberg K, Straub M, et al. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail. 2003 Oct;5(5):659–67.
  337. Hall SA, Cigarroa CG, Marcoux L, Risser RC, Grayburn PA, Eichhorn EJ. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. J Am Coll Cardiol. 1995 Apr;25(5):1154–61.
  338. Tang WHW, Vagelos RH, Yee YG, Benedict CR, Willson K, Liss CL, et al. Neurohormonal and clinical responses to high- versus low-dose enalapril therapy in chronic heart failure. J Am Coll Cardiol. 2002 Jan 2;39(1):70–8.
  339. Finley JJ, Konstam MA, Udelson JE. Arginine vasopressin antagonists for the treatment of heart failure and hyponatremia. Circulation. 2008 Jul 22;118(4):410–21.
  340. Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang CS, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 1990 Nov;82(5):1724–9.
  341. Maisel A, Xue Y, Shah K, Mueller C, Nowak R, Peacock WF, et al. Increased 90-day mortality in patients with acute heart failure with elevated copeptin: secondary results from the Biomarkers in Acute Heart Failure (BACH) study. Circ Heart Fail. 2011 Sep;4(5):613–20.
  342. Lin TE, Adams KF, Patterson JH. Potential roles of vaptans in heart failure: experience from clinical trials and considerations for optimizing therapy in target patients. Heart Fail Clin. 2014 Oct;10(4):607–20.
  343. Januzzi JL. Natriuretic Peptides as Biomarkers in Heart Failure. J Investig Med Off Publ Am Fed Clin Res. 2013 Aug;61(6):950–5.
  344. Kim H-N, Januzzi JL. Natriuretic peptide testing in heart failure. Circulation. 2011 May 10;123(18):2015–9.
  345. van Kimmenade RRJ, Januzzi JL, Bakker JA, Houben AJ, Rennenberg R, Kroon AA, et al. Renal clearance of B-type natriuretic peptide and amino terminal pro-B-type natriuretic peptide a mechanistic study in hypertensive subjects. J Am Coll Cardiol. 2009 Mar 10;53(10):884–90.
  346. Niederkofler EE, Kiernan UA, O’Rear J, Menon S, Saghir S, Protter AA, et al. Detection of endogenous B-type natriuretic peptide at very low concentrations in patients with heart failure. Circ Heart Fail. 2008 Nov;1(4):258–64.
  347. Troughton RW, Frampton CM, Brunner-La Rocca H-P, Pfisterer M, Eurlings LWM, Erntell H, et al. Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis. Eur Heart J. 2014 Jun 14;35(23):1559–67.
  348. Levy WC, Linker DT. Prediction of mortality in patients with heart failure and systolic dysfunction. Curr Cardiol Rep. 2008 May 1;10(3):198–205.
  349. Endothelin receptor antagonists for pulmonary arterial hypertension [Internet]. [cited 2020 Aug 4]. Available from: /CD004434/AIRWAYS_endothelin-receptor-antagonists-for-pulmonary-arterial-hypertension
  350. Westman PC, Lipinski MJ, Luger D, Waksman R, Bonow RO, Wu E, et al. Inflammation as a Driver of Adverse Left Ventricular Remodeling After Acute Myocardial Infarction. J Am Coll Cardiol. 2016 03;67(17):2050–60.
  351. Vasan RS, Sullivan LM, Roubenoff R, Dinarello CA, Harris T, Benjamin EJ, et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation. 2003 Mar 25;107(11):1486–91.
  352. Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013 Jul 23;62(4):263–71.
  353. Mann DL, McMurray JJV, Packer M, Swedberg K, Borer JS, Colucci WS, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation. 2004 Apr 6;109(13):1594–602.
  354. Toldo S, Mezzaroma E, Mauro AG, Salloum F, Van Tassell BW, Abbate A. The inflammasome in myocardial injury and cardiac remodeling. Antioxid Redox Signal. 2015 May 1;22(13):1146–61.
  355. Marchetti C, Chojnacki J, Toldo S, Mezzaroma E, Tranchida N, Rose SW, et al. A novel pharmacologic inhibitor of the NLRP3 inflammasome limits myocardial injury after ischemia-reperfusion in the mouse. J Cardiovasc Pharmacol. 2014 Apr;63(4):316–22.
  356. JCI – Oxygen, oxidative stress, hypoxia, and heart failure [Internet]. [cited 2020 Aug 4]. Available from:
  357. White M, Ducharme A, Ibrahim R, Whittom L, Lavoie J, Guertin M-C, et al. Increased systemic inflammation and oxidative stress in patients with worsening congestive heart failure: improvement after short-term inotropic support. Clin Sci Lond Engl 1979. 2006 Apr;110(4):483–9.
  358. Tang WHW, Brennan M-L, Philip K, Tong W, Mann S, Van Lente F, et al. Plasma myeloperoxidase levels in patients with chronic heart failure. Am J Cardiol. 2006 Sep 15;98(6):796–9.
  359. Ingelsson E, Sundström J, Arnlöv J, Zethelius B, Lind L. Insulin resistance and risk of congestive heart failure. JAMA. 2005 Jul 20;294(3):334–41.
  360. Hc C, Mw S, Jm H. Role of nitric oxide in the pathophysiology of heart failure. Heart Fail Rev. 2003 Jan 1;8(1):35–46.
  361. Nitric Oxide Inhibits Dystrophin Proteolysis by Coxsackieviral Protease 2A Through S-Nitrosylation | Circulation [Internet]. [cited 2020 Aug 4]. Available from:
  362. Regulation of cardiovascular cellular processes by S-nitrosylation [Internet]. [cited 2020 Aug 4]. Available from:
  363. Zannad F, Dousset B, Alla F. Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship. Hypertens Dallas Tex 1979. 2001 Nov;38(5):1227–32.
  364. Wang TJ, Larson MG, Benjamin EJ, Siwik DA, Safa R, Guo C-Y, et al. Clinical and Echocardiographic Correlates of Plasma Pro-collagen Type III Amino-terminal Peptide Levels in the Community. Am Heart J. 2007 Aug;154(2):291–7.
  365. Shalitin N, Schlesinger H, Levy MJ, Kessler E, Kessler‐Icekson G. Expression of procollagen C-proteinase enhancer in cultured rat heart fibroblasts: Evidence for co-regulation with type I collagen. J Cell Biochem. 2003;90(2):397–407.
  366. Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie ANJ, Lee RT. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest. 2007 Jun;117(6):1538–49.
  367. Yancy Clyde W., Jessup Mariell, Bozkurt Biykem, Butler Javed, Casey Donald E., Drazner Mark H., et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure. Circulation. 2013 Oct 15;128(16):e240–327.
  368. Januzzi JL, Peacock WF, Maisel AS, Chae CU, Jesse RL, Baggish AL, et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J Am Coll Cardiol. 2007 Aug 14;50(7):607–13.
  369. Sharma UC, Pokharel S, van Brakel TJ, van Berlo JH, Cleutjens JPM, Schroen B, et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation. 2004 Nov 9;110(19):3121–8.
  370. Gullestad L, Ueland T, Kjekshus J, Nymo SH, Hulthe J, Muntendam P, et al. Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Eur Heart J. 2012 Sep;33(18):2290–6.
  371. Bayes-Genis A, de Antonio M, Vila J, Peñafiel J, Galán A, Barallat J, et al. Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3. J Am Coll Cardiol. 2014 Jan 21;63(2):158–66.
  372. Apoptosis Repressor With Caspase Recruitment Domain Is Required for Cardioprotection in Response to Biomechanical and Ischemic Stress | Circulation [Internet]. [cited 2020 Aug 4]. Available from:
  373. Olivetti G, Abbi R, Quaini F, Kajstura J, Cheng W, Nitahara JA, et al. Apoptosis in the failing human heart. N Engl J Med. 1997 Apr 17;336(16):1131–41.
  374. Anand IS, Kempf T, Rector TS, Tapken H, Allhoff T, Jantzen F, et al. Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial. Circulation. 2010 Oct 5;122(14):1387–95.
  375. Meta-analysis of stem cell therapy in chronic ischemic cardiomyopathy. – Abstract – Europe PMC [Internet]. [cited 2020 Aug 4]. Available from:
  376. Malliaras K, Makkar RR, Smith RR, Cheng K, Wu E, Bonow RO, et al. Intracoronary cardiosphere-derived cells after myocardial infarction: evidence of therapeutic regeneration in the final 1-year results of the CADUCEUS trial (CArdiosphere-Derived aUtologous stem CElls to reverse ventricUlar dySfunction). J Am Coll Cardiol. 2014 Jan 21;63(2):110–22.
  377. Malliaras K, Li T-S, Luthringer D, Terrovitis J, Cheng K, Chakravarty T, et al. Safety and Efficacy of Allogeneic Cell Therapy in Infarcted Rats Transplanted with Mismatched Cardiosphere-Derived Cells. Circulation. 2012 Jan 3;125(1):100–12.
  378. Greenberg B, Butler J, Felker GM, Ponikowski P, Voors AA, Desai AS, et al. Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial. Lancet Lond Engl. 2016 Mar 19;387(10024):1178–86.
  379. Coronary endothelial dysfunction in patients with acute-onset idiopathic dilated cardiomyopathy – PubMed [Internet]. [cited 2020 Aug 4]. Available from:
  380. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling–concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol. 2000 Mar 1;35(3):569–82.
  381. Narula J, Haider N, Virmani R, DiSalvo TG, Kolodgie FD, Hajjar RJ, et al. Apoptosis in myocytes in end-stage heart failure. N Engl J Med. 1996 Oct 17;335(16):1182–9.
  382. Kajstura J, Leri A, Finato N, Di Loreto C, Beltrami CA, Anversa P. Myocyte proliferation in end-stage cardiac failure in humans. Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8801–5.
  383. Gerdes AM, Kellerman SE, Moore JA, Muffly KE, Clark LC, Reaves PY, et al. Structural remodeling of cardiac myocytes in patients with ischemic cardiomyopathy. Circulation. 1992 Aug;86(2):426–30.
  384. Congestive cardiac failure: central role of the arterial blood pressure. [Internet]. [cited 2020 Aug 4]. Available from:
  385. Onodera Tatsuyuki, Tamura Tetsutaro, Said Suleman, McCune Sylvia A., Gerdes A. Martin. Maladaptive Remodeling of Cardiac Myocyte Shape Begins Long Before Failure in Hypertension. Hypertension. 1998 Oct 1;32(4):753–7.
  386. Thibodeau JT, Turer AT, Gualano SK, Ayers CR, Velez-Martinez M, Mishkin JD, et al. Characterization of a novel symptom of advanced heart failure: bendopnea. JACC Heart Fail. 2014 Feb;2(1):24–31.
  387. Tang Y-D, Katz SD. Anemia in chronic heart failure: prevalence, etiology, clinical correlates, and treatment options. Circulation. 2006 May 23;113(20):2454–61.
  388. Auer J. What does the liver tell us about the failing heart? Eur Heart J. 2013 Mar 7;34(10):711–4.
  389. Schrier RW. Cardiorenal versus renocardiac syndrome: is there a difference? Nat Clin Pract Nephrol. 2007 Dec;3(12):637.
  390. Impaired Baroreceptor Control of Renal Sympathetic Activity in Human Chronic Heart Failure | Circulation [Internet]. [cited 2020 Aug 4]. Available from:
  391. Luchner A, Hengstenberg C, Löwel H, Riegger GAJ, Schunkert H, Holmer S. Effect of compensated renal dysfunction on approved heart failure markers: direct comparison of brain natriuretic peptide (BNP) and N-terminal pro-BNP. Hypertens Dallas Tex 1979. 2005 Jul;46(1):118–23.
  392. Angermann CE, Frey A, Ertl G. Cognition matters in cardiovascular disease and heart failure. Eur Heart J. 2012 Jul;33(14):1721–3.
  393. Gnanasekaran G. Epidemiology of depression in heart failure. Heart Fail Clin. 2011 Jan;7(1):1–10.
  394. Pacher P, Kecskemeti V. Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns? Curr Pharm Des. 2004;10(20):2463–75.
  395. Nicholson C. Chronic heart failure: pathophysiology, diagnosis and treatment. Nurs Older People. 2014 Aug;26(7):29–38.
  396. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med. 1971 Dec 23;285(26):1441–6.
  397. Carlson KJ, Lee DC, Goroll AH, Leahy M, Johnson RA. An analysis of physicians’ reasons for prescribing long-term digitalis therapy in outpatients. J Chronic Dis. 1985;38(9):733–9.
  398. Eriksson H, Caidahl K, Larsson B, Ohlson LO, Welin L, Wilhelmsen L, et al. Cardiac and pulmonary causes of dyspnoea–validation of a scoring test for clinical-epidemiological use: the Study of Men Born in 1913. Eur Heart J. 1987 Sep;8(9):1007–14.
  399. Dunlay SM, Roger VL. Understanding the Epidemic of Heart Failure: Past, Present, and Future. Curr Heart Fail Rep. 2014 Dec;11(4):404–15.
  400. Di Bari M, Pozzi C, Cavallini MC, Innocenti F, Baldereschi G, De Alfieri W, et al. The diagnosis of heart failure in the community. Comparative validation of four sets of criteria in unselected older adults: the ICARe Dicomano Study. J Am Coll Cardiol. 2004 Oct 19;44(8):1601–8.
  401. Grote Beverborg N, van Veldhuisen DJ, van der Meer P. Anemia in Heart Failure: Still Relevant? JACC Heart Fail. 2018;6(3):201–8.
  402. Hoes MF, Grote Beverborg N, Kijlstra JD, Kuipers J, Swinkels DW, Giepmans BNG, et al. Iron deficiency impairs contractility of human cardiomyocytes through decreased mitochondrial function. Eur J Heart Fail. 2018;20(5):910–9.
  403. Al‐Naher A, Wright D, Devonald MAJ, Pirmohamed M. Renal function monitoring in heart failure – what is the optimal frequency? A narrative review. Br J Clin Pharmacol. 2018 Jan;84(1):5–17.
  404. Alvarez AM, Mukherjee D. Liver Abnormalities in Cardiac Diseases and Heart Failure. Int J Angiol Off Publ Int Coll Angiol Inc. 2011 Sep;20(3):135–42.
  405. Ischemic Heart Disease | Harrison’s Principles of Internal Medicine, 20e | AccessPharmacy | McGraw-Hill Medical [Internet]. [cited 2020 Aug 10]. Available from:
  406. Fisher C, Berry C, Blue L, Morton JJ, McMurray J. N-terminal pro B type natriuretic peptide, but not the new putative cardiac hormone relaxin, predicts prognosis in patients with chronic heart failure. Heart Br Card Soc. 2003 Aug;89(8):879–81.
  407. Cheng V, Kazanagra R, Garcia A, Lenert L, Krishnaswamy P, Gardetto N, et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol. 2001 Feb;37(2):386–91.
  408. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017 08;136(6):e137–61.
  409. Song BG, Jeon ES, Kim YH, Kang MK, Doh JH, Kim PH, et al. Correlation between levels of N-terminal pro-B-type natriuretic peptide and degrees of heart failure. Korean J Intern Med. 2005 Mar;20(1):26–32.
  410. Dao Q, Krishnaswamy P, Kazanegra R, Harrison A, Amirnovin R, Lenert L, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol. 2001 Feb;37(2):379–85.
  411. Redfield MM. Heart failure–an epidemic of uncertain proportions. N Engl J Med. 2002 Oct 31;347(18):1442–4.
  412. St Peter JV, Hartley GG, Murakami MM, Apple FS. B-type natriuretic peptide (BNP) and N-terminal pro-BNP in obese patients without heart failure: relationship to body mass index and gastric bypass surgery. Clin Chem. 2006 Apr;52(4):680–5.
  413. Rivera M, Cortés R, Salvador A, Bertomeu V, de Burgos FG, Payá R, et al. Obese subjects with heart failure have lower N-terminal pro-brain natriuretic peptide plasma levels irrespective of aetiology. Eur J Heart Fail. 2005 Dec;7(7):1168–70.
  414. Seino Y, Ogawa A, Yamashita T, Fukushima M, Ogata K, Fukumoto H, et al. Application of NT-proBNP and BNP measurements in cardiac care: a more discerning marker for the detection and evaluation of heart failure. Eur J Heart Fail. 2004 Mar 15;6(3):295–300.
  415. Ezekowitz JA, Hernandez AF, Starling RC, Yancy CW, Massie B, Hill JA, et al. Standardizing care for acute decompensated heart failure in a large megatrial: the approach for the Acute Studies of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure (ASCEND-HF). Am Heart J. 2009 Feb;157(2):219–28.
  416. Fitzgerald RL, Cremo R, Gardetto N, Chiu A, Clopton P, Bhalla V, et al. Effect of nesiritide in combination with standard therapy on serum concentrations of natriuretic peptides in patients admitted for decompensated congestive heart failure. Am Heart J. 2005 Sep;150(3):471–7.
  417. Demissei BG, Postmus D, Cleland JG, O’Connor CM, Metra M, Ponikowski P, et al. Plasma biomarkers to predict or rule out early post-discharge events after hospitalization for acute heart failure. Eur J Heart Fail. 2017;19(6):728–38.
  418. de Boer RA, Nayor M, deFilippi CR, Enserro D, Bhambhani V, Kizer JR, et al. Association of Cardiovascular Biomarkers With Incident Heart Failure With Preserved and Reduced Ejection Fraction. JAMA Cardiol. 2018 01;3(3):215–24.
  419. Imran TF, Shin HJ, Mathenge N, Wang F, Kim B, Joseph J, et al. Meta-Analysis of the Usefulness of Plasma Galectin-3 to Predict the Risk of Mortality in Patients With Heart Failure and in the General Population. Am J Cardiol. 2017 Jan 1;119(1):57–64.
  420. Di Tano G, Caretta G, De Maria R, Bettari L, Parolini M, Testa S, et al. Galectin-3 and outcomes after anterior-wall myocardial infarction treated by primary percutaneous coronary intervention. Biomark Med. 2018 Jan;12(1):21–6.
  421. van Vark LC, Lesman-Leegte I, Baart SJ, Postmus D, Pinto YM, de Boer RA, et al. Prognostic Value of Serial Galectin-3 Measurements in Patients With Acute Heart Failure. J Am Heart Assoc. 2017 Nov 29;6(12).
  422. Binas D, Daniel H, Richter A, Ruppert V, Schlüter K-D, Schieffer B, et al. The prognostic value of sST2 and galectin-3 considering different aetiologies in non-ischaemic heart failure. Open Heart. 2018 Feb;5(1):e000750.
  423. Circulating biomarkers in heart failure: diagnostic and prognostic importance – Berezin – Journal of Laboratory and Precision Medicine [Internet]. [cited 2020 Aug 5]. Available from:
  424. Doumouras BS, Lee DS, Levy WC, Alba AC. An Appraisal of Biomarker-Based Risk-Scoring Models in Chronic Heart Failure: Which One Is Best? Curr Heart Fail Rep. 2018;15(1):24–36.
  425. Boulogne M, Sadoune M, Launay JM, Baudet M, Cohen-Solal A, Logeart D. Inflammation versus mechanical stretch biomarkers over time in acutely decompensated heart failure with reduced ejection fraction. Int J Cardiol. 2017 Jan 1;226:53–9.
  426. Heart Failure Society of America, Lindenfeld J, Albert NM, Boehmer JP, Collins SP, Ezekowitz JA, et al. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail. 2010 Jun;16(6):e1-194.
  427. Baig MK, Goldman JH, Caforio AL, Coonar AS, Keeling PJ, McKenna WJ. Familial dilated cardiomyopathy: cardiac abnormalities are common in asymptomatic relatives and may represent early disease. J Am Coll Cardiol. 1998 Jan;31(1):195–201.
  428. Peretto G, Sala S, Benedetti S, Di Resta C, Gigli L, Ferrari M, et al. Updated clinical overview on cardiac laminopathies: an electrical and mechanical disease. Nucleus. 2018 Oct 3;9(1):380–91.
  429. Marian AJ, Braunwald E. Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy. Circ Res. 2017 Sep 15;121(7):749–70.
  430. Teo LYL, Moran RT, Tang WHW. Evolving Approaches to Genetic Evaluation of Specific Cardiomyopathies. Curr Heart Fail Rep. 2015 Dec 1;12(6):339–49.
  431. McNally E, MacLeod H, Dellefave-Castillo L. Arrhythmogenic Right Ventricular Cardiomyopathy [Internet]. GeneReviews® [Internet]. University of Washington, Seattle; 2017 [cited 2020 Aug 4]. Available from:
  432. Bayes-Genis A, Ordonez-Llanos J. Multiple biomarker strategies for risk stratification in heart failure. Clin Chim Acta Int J Clin Chem. 2015 Mar 30;443:120–5.
  433. Mueller‐Lenke N, Rudez J, Staub D, Laule‐Kilian K, Klima T, Perruchoud AP, et al. Use of chest radiography in the emergency diagnosis of acute congestive heart failure. Heart. 2006 May;92(5):695–6.
  434. Gupta VA, Nanda NC, Sorrell VL. Role of Echocardiography in the Diagnostic Assessment and Etiology of Heart Failure in Older Adults: Opacify, Quantify, and Rectify. Heart Fail Clin. 2017 Jul;13(3):445–66.
  435. Assessment and impact of diastolic function by echocardiography in elderly patients [Internet]. [cited 2020 Aug 4]. Available from:
  436. Meersch M, Schmidt C, Zarbock A. Echophysiology: the transesophageal echo probe as a noninvasive Swan-Ganz catheter. Curr Opin Anaesthesiol. 2016 Feb;29(1):36–45.
  437. Kim RJ, Wu E, Rafael A, Chen EL, Parker MA, Simonetti O, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med. 2000 Nov 16;343(20):1445–53.
  438. Ritchie JL, Bateman TM, Bonow RO, Crawford MH, Gibbons RJ, Hall RJ, et al. Guidelines for clinical use of cardiac radionuclide imaging. Report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Committee on Radionuclide Imaging), developed in collaboration with the American Society of Nuclear Cardiology. J Am Coll Cardiol. 1995 Feb;25(2):521–47.
  439. Sabharwal NK, Lahiri A. Role of myocardial perfusion imaging for risk stratification in suspected or known coronary artery disease. Heart. 2003 Nov;89(11):1291–7.
  440. Taillefer R, DePuey EG, Udelson JE, Beller GA, Latour Y, Reeves F. Comparative diagnostic accuracy of Tl-201 and Tc-99m sestamibi SPECT imaging (perfusion and ECG-gated SPECT) in detecting coronary artery disease in women. J Am Coll Cardiol. 1997 Jan;29(1):69–77.
  441. Bonow RO, Maurer G, Lee KL, Holly TA, Binkley PF, Desvigne-Nickens P, et al. Myocardial viability and survival in ischemic left ventricular dysfunction. N Engl J Med. 2011 Apr 28;364(17):1617–25.
  442. Binanay C, Califf RM, Hasselblad V, O’Connor CM, Shah MR, Sopko G, et al. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA. 2005 Oct 5;294(13):1625–33.
  443. Right heart catheterisation: best practice and pitfalls in pulmonary hypertension | European Respiratory Society [Internet]. [cited 2020 Aug 5]. Available from:
  444. Nair R, Lamaa N. Pulmonary Capillary Wedge Pressure [Internet]. StatPearls [Internet]. StatPearls Publishing; 2020 [cited 2020 Aug 5]. Available from:
Clinical Profile Of Refractory Heart Failure And Its Outcome In Rural Institutional Setup